MARKET NEWS

CureVac Granted Patent Claiming the Combination of mRNA Vaccines With Anti-PD-L1 Antibodies
Rexahn & BioSense Global Announce Collaboration & License Agreement
Kamada Announces FDA Acceptance of Inhaled AAT Program
Enesi Pharma & BARDA Drive Enter Public-Private Partnership to Develop Solid Dose Vaccine Delivery Technology
Fibrocell Announces Development & Commercialization Collaboration With Castle Creek Pharmaceuticals
Biotechpharma to Expand Process Development & GMP Manufacturing Capacity

  FEATURED EDITORIAL

  COMPANY PROFILE

Frontage is a CRO providing integrated, scientifically driven research, analytical, and development services throughout the drug discovery and development process to enable biopharmaceutical companies to achieve their drug development goals. We offer our clients comprehensive services in analytical testing and formulation development, drug metabolism, and pharmacokinetics (DMPK), bioanalysis, preclinical safety and toxicology, and early phase clinical studies. We have enabled many innovator, generic and consumer health companies of all sizes to file IND, NDA, ANDA, BLA and 505(b)(2) submissions in global markets allowing for successful development of important therapies and products for patients. We successfully assist clients to advance hundreds of molecules through development to commercial launch in global markets. We are committed to providing rigorous scientific expertise to ensure the highest quality and compliance. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial

Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial

Soligenix, Inc. recently announced today it has reached a significant milestone in the Phase 3 clinical study (the “DOM-INNATE” study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC).

Hovione Technology Announces Acquisition of Global Rights to New Pulmonary Inhaler Device

Hovione Technology Announces Acquisition of Global Rights to New Pulmonary Inhaler Device

Hovione Technology, a specialist in development of innovative inhalation device technology, recently announced it has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler patented by inventor Dr. Klaus-Dieter Beller.

Paragon Bioservices to be Acquired for .2 Billion

Paragon Bioservices to be Acquired for $1.2 Billion

Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

May 1 – Formulation Development
May 8 – Prefilled Syringes